The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its ...

The FDA has decided to reconsider its previous decision that barred drug compounders from selling their versions of Eli Lilly ...

The FDA has agreed to revisit its decision to prevent compounders from selling versions of Eli Lilly's diabetes and weight ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Rival manufacturers fight for the right to sell weight loss drugsThere’s a new fight brewing between ...

In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Teva Pharmaceutical Industries will pay $450 to settle the Department of Justice's investigation into allegations of price fixing and misuse of funds for kickbacks. Other pharmaceutical news reports ...

Last week, the FDA determined the shortage of Eli Lilly tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, ...